Kadmon Holdings, Inc. (KDMN): Price and Financial Metrics

Kadmon Holdings, Inc. (KDMN): $9.50

0.02 (+0.21%)

POWR Rating

Component Grades













Add KDMN to Watchlist
Sign Up

Industry: Biotech


of 483

in industry


  • KDMN scores best on the Growth dimension, with a Growth rank ahead of 28.46% of US stocks.
  • The strongest trend for KDMN is in Sentiment, which has been heading down over the past 52 weeks.
  • KDMN's current lowest rank is in the Stability metric (where it is better than 2.59% of US stocks).

KDMN Stock Summary

  • With a price/sales ratio of 105.46, Kadmon Holdings Inc has a higher such ratio than 96.56% of stocks in our set.
  • With a year-over-year growth in debt of 948.92%, Kadmon Holdings Inc's debt growth rate surpasses 98.39% of about US stocks.
  • In terms of volatility of its share price, KDMN is more volatile than 95.9% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Kadmon Holdings Inc, a group of peers worth examining would be KPTI, FBIO, ENTX, EPZM, and INFN.
  • KDMN's SEC filings can be seen here. And to visit Kadmon Holdings Inc's official web site, go to www.kadmon.com.

KDMN Valuation Summary

  • In comparison to the median Healthcare stock, KDMN's EV/EBIT ratio is 135.84% lower, now standing at -10.5.
  • KDMN's price/sales ratio has moved up 494.1 over the prior 62 months.
  • KDMN's price/sales ratio has moved up 494.1 over the prior 62 months.

Below are key valuation metrics over time for KDMN.

Stock Date P/S P/B P/E EV/EBIT
KDMN 2021-08-31 506.4 28.2 -8.3 -10.5
KDMN 2021-08-30 487.9 27.2 -8.0 -10.2
KDMN 2021-08-27 494.4 27.6 -8.1 -10.3
KDMN 2021-08-26 500.9 27.9 -8.2 -10.4
KDMN 2021-08-25 497.2 27.7 -8.2 -10.3
KDMN 2021-08-24 498.1 27.8 -8.2 -10.4

KDMN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KDMN has a Quality Grade of D, ranking ahead of 21.97% of graded US stocks.
  • KDMN's asset turnover comes in at 0.007 -- ranking 401st of 680 Pharmaceutical Products stocks.
  • CLSN, ACAD, and PBYI are the stocks whose asset turnover ratios are most correlated with KDMN.

The table below shows KDMN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.007 0.618 -0.416
2021-03-31 0.009 0.298 -0.707
2020-12-31 0.044 0.759 -1.846
2020-09-30 0.060 0.837 -1.639
2020-06-30 0.062 0.858 -2.205
2020-03-31 0.060 0.839 -1.051

KDMN Price Target

For more insight on analysts targets of KDMN, see our KDMN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.10 Average Broker Recommendation 1.83 (Hold)

KDMN Stock Price Chart Interactive Chart >

Price chart for KDMN

KDMN Price/Volume Stats

Current price $9.50 52-week high $9.50
Prev. close $9.48 52-week low $3.19
Day low $9.48 Volume 10,424,500
Day high $9.50 Avg. volume 5,109,463
50-day MA $8.58 Dividend yield N/A
200-day MA $5.34 Market Cap 1.70B

Kadmon Holdings, Inc. (KDMN) Company Bio

Kadmon Holdings, LLC discovers, develops, and commercializes small molecules and biologics to address unmet medical needs. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. The company is based in New York City, New York

KDMN Latest News Stream

Event/Time News Detail
Loading, please wait...

KDMN Latest Social Stream

Loading social stream, please wait...

View Full KDMN Social Stream

Latest KDMN News From Around the Web

Below are the latest news stories about Kadmon Holdings Inc that investors may wish to consider to help them evaluate KDMN as an investment opportunity.

Is Kadmon Holdings, Inc. (KDMN) A Good Stock To Buy?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 873 world-class investment firms that we track and now have access to the collective wisdom contained in […]

Yahoo | October 25, 2021

38 Stocks Moving In Thursday's Mid-Day Session

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 132.3% to $23.14 following an announcement the company will merge with Trump Media & Technology Group. Portillo's Inc. (NASDAQ: PTLO) gained 45.9% to $29.18 after the company priced its IPO at $20 per share. TriState Capital Holdings, Inc. (NASDAQ: TSC) shares jumped 32.1% to $30.06 after Raymond James Financial announced it will acquire the company. TriState Capital announced better-than-expected Q3 earnings. China Finance Onl

Yahoo | October 21, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGP, ESBK, KDMN, VNE; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Teekay LNG Partners L. (NYSE:TGP)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Stonepeak for $17.

Yahoo | October 8, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | October 8, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Shareholders are Encouraged to Contact the Firm

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ: XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck & Co., Inc. for $180.00 per share in cash. If you are an Acceleron shareholder, click here to learn more about your rights and options. ADTRAN, Inc. (NASDAQ: ADTN) concerning potenti

Yahoo | October 4, 2021

Read More 'KDMN' Stories Here

KDMN Price Returns

1-mo N/A
3-mo 1.01%
6-mo 125.65%
1-year 96.08%
3-year 318.50%
5-year 91.53%
2021 0.00%
2020 -8.39%
2019 117.79%
2018 -42.54%
2017 -32.34%

Continue Researching KDMN

Here are a few links from around the web to help you further your research on Kadmon Holdings Inc's stock as an investment opportunity:

Kadmon Holdings Inc (KDMN) Stock Price | Nasdaq
Kadmon Holdings Inc (KDMN) Stock Quote, History and News - Yahoo Finance
Kadmon Holdings Inc (KDMN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8169 seconds.